Aerolase Reverse Protocol: 1064nm Nd:YAG + 2940nm Er:YAG Synergistic Skin Rejuvenation | IMCAS 2026

‍

In this IMCAS 2026 presentation from Paris, Dr. Francisca Kartono explains the science and clinical rationale behind the Aerolase Reverse protocol — a dual-wavelength approach that combines nonablative 1064nm Nd:YAG laser treatment with ablative 2940nm Er:YAG laser resurfacing to treat both the dermal and epidermal layers of the skin in a single session.

Dr. Kartono breaks down why a synergistic, multi-modality laser protocol delivers superior patient outcomes compared to single-wavelength treatments alone. She covers how the 1064nm Nd:YAG laser achieves nonablative dermal remodeling and neocollagenesis by targeting the skin's primary chromophores — hemoglobin, melanin, and water — while the 2940nm Er:YAG ablative laser addresses the superficial epidermal layer, enabling full-thickness skin rejuvenation from the dermis up.

Key Topics Covered:

• Why synergistic laser protocols improve clinical outcomes for skin rejuvenation.
• How combining nonablative and ablative modalities treats skin from bottom to top. 
• The role of 1064nm Nd:YAG microsecond laser technology in dermal remodeling and neocollagenesis.
• How 2940nm Er:YAG ablative resurfacing complements deeper dermal treatments.
• Saving patients time and money with multi-modality treatment plans.
• When to recommend the Reverse protocol in your aesthetic or dermatology practice.

Presented by Francisca Kartono, DO, FAOCD, FAAD

Board-certified dermatologist and the owner and medical director of MI Skin Center in Northville, MI. Dr. Kartono earned her Biochemistry degree from UCLA, attended Western University of Health Sciences for medical school, and completed her dermatology residency through Michigan State University. She has served as an assistant clinical professor at Ohio State University Medical Center and is currently faculty at multiple residency programs at Trinity Health and Beaumont Hospital System. Dr. Kartono has published extensively, lectured nationally, participated in clinical trials, and was recently appointed President of the American Osteopathic College of Dermatology.